Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12359725
Lents NH, Keenan SM, Bellone C, Baldassare JJ (2002) Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2. J Biol Chem 277, 47469-75 12359725
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

T160-p - CDK2 (human)
Modsite: GVPVRtytHEVVtLW SwissProt Entrez-Gene
Orthologous residues
CDK2 (human): T160‑p, CDK2 iso2 (human): T160‑p, CDK2 (mouse): T160‑p, CDK2 (rat): T160‑p
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  IIC9 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  hamster
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, transfection of dominant-negative enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, transfection of dominant-negative enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease
LY294002 increase
serum increase
Downstream Regulation
Effect of modification (function):  activity, induced